Clare Rowntree

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Rachel Wade et al. · The Lancet Oncology · 2013 · 483 citations · Full text

Medicine, Hematology, Oncology +16

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

Ajay Vora, Nick Goulden, Chris Mitchell et al. · The Lancet Oncology · 2014 · 305 citations · Full text

Medicine, Oncology, Pediatrics +13

Outcome for children and young people with <scp>E</scp>arly <scp>T</scp>‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, <scp>UKALL</scp> 2003

Katharine Patrick, Rachel Wade, Nick Goulden et al. · British Journal of Haematology · 2014 · 230 citations

Medicine, Oncology, Pediatrics +10

The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

Saman Hewamana, Suhair Alghazal, Thet Thet Lin et al. · Blood · 2008 · 156 citations · Full text

Medicine, Molecular Biology, Oncology +13

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

F Mindlen, Roberto Nordaby, M I Soto Ruiz et al. · Queensland's institutional digital repository (The University of Queensland) · 1996 · 154 citations

Medicine, Cardiology, Pharmacotherapy +17